相关实验视频

Updated: Jul 19, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

在口腔癌中非编码RNA:新兴的角色和临床应用

Saurabh Dey¹, Bini Biswas¹, Angela Manoj Appadan¹

¹Cancer and Translational Research Centre, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth (DPU), Pimpri 411033, India.

|August 12, 2023

概括

非编码RNAs (ncRNAs) 在口腔癌 (OC) 管理中表现出显著的潜力. 这些分子,包括微RNA (miRNA) 和长非编码RNA (lncRNA),可以作为口腔癌的诊断标记物和治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

口腔癌 (OC) 是一个全球性的健康问题,治疗结果低于最佳.
在OC发病率的区域差异与饮食,烟草和酒精使用等生活方式因素有关.
目前对OC的治疗策略需要通过更好地了解疾病机制来加强.

研究的目的:

审查各种非编码RNAs (ncRNAs) 在口腔癌中的新兴作用.
突出ncRNAs作为OC的诊断,预后和治疗剂的临床潜力.
巩固目前关于ncRNA参与OC发作,进展和治疗耐药性的知识.

主要方法:

文献综述侧重于口腔癌 (OC) 中的非编码RNA (ncRNA).
在OC中研究微RNA (miRNA),长ncRNA (lncRNA),循环RNA (circRNA),PIWI相互作用RNA (piRNA) 和小核RNA (snoRNA) 的研究分析.
检查细胞通路中的ncRNA失调及其在生物样本中的检测.

主要成果:

失调的ncRNAs表达,特别是miRNAs,lncRNAs和circRNAs,与OC发展,进展和治疗耐药性有关.
ncRNAs通过表观遗传,转录,后转录和翻译机制调节关键细胞通路.
在血液,唾液和细胞外囊中的miRNAs和lncRNAs的差异表达表明了诊断和预后价值.

结论:

非编码RNAs (ncRNAs) 在口腔癌 (OC) 研究和临床应用中是一个有希望的前沿.
ncRNAs为早期诊断和预后提供了新的生物标志物的潜力.
向ncRNAs是一个可行的治疗策略,可以改善OC治疗结果.

关键词:

PIWI-交互RNA (piRNA) 是一种与PIWI交互的RNA.癌症的诊断癌症的诊断癌症治疗疗法癌症治疗循环RNA (循环RNA) 是一种循环RNA.头部和部癌症头部和部癌症长非编码RNA (lncRNA) 是一种长非编码RNA.微RNA (miRNA) 是一种微型RNA.没有编码的RNA.口腔癌是口腔癌的一种疾病.小核RNA (snoRNA) 是一种小核RNA.

更多相关视频

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...